Idera Pharmaceuticals Inc


Prices are adjusted according to historical splits.

Idera Pharmaceuticals Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$26.50 million
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Idera Pharmaceuticals Inc had its IPO on 1996-01-24 under the ticker symbol IDRA.

The company operates in the Healthcare sector and Biotechnology industry. Idera Pharmaceuticals Inc has a staff strength of 13 employees.

Stock update

Shares of Idera Pharmaceuticals Inc opened at $8.11 at the start of the last trading session i.e. 2023-03-24.

The stocks traded within a range of $7.14 - $8.67, and closed at $7.23.

This is a -21.57% slip from the previous day's closing price.

A total volume of 21,875 shares were traded at the close of the day’s session.

In the last one week, shares of Idera Pharmaceuticals Inc have increased by +917.75%.

Idera Pharmaceuticals Inc's Key Ratios

Idera Pharmaceuticals Inc has a market cap of $26.50 million, indicating a price to book ratio of 0.841 and a price to sales ratio of 349.9538.

In the last 12-months Idera Pharmaceuticals Inc’s revenue was $49000 with a gross profit of $-9247000 and an EBITDA of $-17341000. The EBITDA ratio measures Idera Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Idera Pharmaceuticals Inc’s operating margin was -35422.45% while its return on assets stood at -15.19% with a return of equity of -32.32%.

In Q3, Idera Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.

Idera Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-0.442 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Idera Pharmaceuticals Inc’s profitability.

Idera Pharmaceuticals Inc stock is trading at a EV to sales ratio of 25.277 and a EV to EBITDA ratio of 0.383. Its price to sales ratio in the trailing 12-months stood at 349.9538.

Idera Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$103.68 million
Total Liabilities
$19.23 million
Operating Cash Flow
$5.48 million
Capital Expenditure
Dividend Payout Ratio

Idera Pharmaceuticals Inc ended 2023 with $103.68 million in total assets and $0 in total liabilities. Its intangible assets were valued at $103.68 million while shareholder equity stood at $20.77 million.

Idera Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $19.23 million in other current liabilities, 59000.00 in common stock, $-748045000.00 in retained earnings and $9.93 million in goodwill. Its cash balance stood at $26.80 million and cash and short-term investments were $26.80 million. The company’s total short-term debt was $245,000 while long-term debt stood at $0.

Idera Pharmaceuticals Inc’s total current assets stands at $30.07 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.96 million compared to accounts payable of $6.76 million and inventory worth $0.

In 2023, Idera Pharmaceuticals Inc's operating cash flow was $5.48 million while its capital expenditure stood at $0.

Comparatively, Idera Pharmaceuticals Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Idera Pharmaceuticals Inc stock is currently trading at $7.23 per share. It touched a 52-week high of $9.5209 and a 52-week low of $9.5209. Analysts tracking the stock have a 12-month average target price of $7.8333.

Its 50-day moving average was $0.68 and 200-day moving average was $0.52 The short ratio stood at 3.14 indicating a short percent outstanding of 0%.

Around 2955.9% of the company’s stock are held by insiders while 552.2% are held by institutions.

Frequently Asked Questions About Idera Pharmaceuticals Inc

The stock symbol (also called stock or share ticker) of Idera Pharmaceuticals Inc is IDRA

The IPO of Idera Pharmaceuticals Inc took place on 1996-01-24

Similar Industry Stocks (Biotechnology)

Last Price

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price
Imara Inc (IMRA)


Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.


505 Eagleview Boulevard, Exton, PA, United States, 19341